-
CONTACTContact Information
- Address: 8F, 55 Magokdong-ro, Gangseo-gu, Seoul, Republic of Korea(07802)
- Business Registration No.: 109-86-37282
- CEO: Choongseong Han
- Tel: +82-2-2088-8886
- Fax: +82-2-2088-8884
- E-mail: support@nexel.co.kr
-
News
- Home
- News
- News
News
Total 16
'Curi Bio' Announces Exclusive Distribution and Services Partnership with 'NEXEL'
“Next Year’s IPO Goal... We’ll be Leading the iPSC Market,” Says Choongseong Han, CEO of NEXEL
Bio Venture Company NEXEL Takes its First Step toward being Listed on KOSDAQ After Being Certified as a Company Specializing in Materials, Parts, and Equipment (MPE)
NEXEL earns Korean Industry Technology certification for So-Bu-Jang specialization from KEIT
NEXEL Earns the First ISO/IEC 17025:2017 Accreditation for iPSC-derived Cardiomyocyte-based Cardiac Safety Testing
Celogics highlights its iPSC derived Cardiomyocytes at the Society of Toxicology (SOT) Annual Meeting and Tox Expo
Celogics Licenses in NEXEL's Cardiosight-S for Global Distribution
Nexel, 'Chinese Patent Registration' for New Drug Candidate for NASH Fibrosis
Curi Bio and NEXEL Announce Celogics, Joint Venture to Develop Leading iPSC-derived Cell Products
NEXEL Co., Ltd. signed Strategic Business Partnership Agreement with Next&Bio